Sigma Healthcare Limited (ASX:SIG) Upgrades FY25 EBIT Guidance
Sigma Healthcare (ASX:SIG) upgrades its FY25 EBIT guidance to $64-$70 million, driven by improved operational performance and strong contract execution.
Category: Healthcare
Acrux Limited (ASX:ACR) CEO Michael Kotsanis to Retire
Acrux Limited (ASX:ACR) CEO Michael Kotsanis announces retirement, initiating search for a successor to ensure a smooth transition.
Actinogen Medical (ASX:ACW) Publishes Clinical Pharmacology Study on Xanamem
Actinogen Medical (ASX:ACW) publishes study validating the 10 mg dose of Xanamem for CNS disease treatment, supporting ongoing clinical trials.
Visionflex Group Limited (ASX:VFX) Updates Financing Facilities
Visionflex Group (ASX:VFX) updates its financing facilities and available funding for Q4 2024.
Micro-X Ltd (ASX:MX1) Announces $6.0M Capital Raising
Micro-X Ltd (ASX:MX1) secures $6M capital raising and a strategic $2.4M investment to advance its focus on medical imaging.
Recce Pharmaceuticals Ltd (ASX:RCE) Corrects Quarterly Cash Flow Report
Recce Pharmaceuticals Ltd (ASX:RCE) corrects its Q4 2024 Cash Flow Report, reflecting positive net operating cash inflows.
Arovella Therapeutics Limited (ASX:ALA) Announces Trading Halt
Arovella Therapeutics (ASX:ALA) requests a trading halt pending a material update related to its recent capital raising placement.
ImpediMed Limited (ASX:IPD) Secures US$15 Million Growth Capital Facility
ImpediMed Limited (ASX:IPD) secures US$15M growth capital facility to support the expansion of its digital health platform.
AdAlta Limited (ASX:1AD) Advances ‘East to West’ Immunotherapy Strategy
AdAlta Limited (ASX:1AD) accelerates its ‘East to West’ cellular immunotherapy strategy, signing additional term sheets to enhance pipeline growth.
Cynata Therapeutics (ASX:CYP) Publishes Comparative Study on MSCs
Cynata Therapeutics (ASX:CYP) publishes study comparing Cymerus™ iPSC-derived MSCs to conventional MSCs, highlighting enhanced functionality and consistency.